A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II

American Journal of Clinical Pathology

Volumn 123, Issue 2, 2005, Pages 250-255

  Castle, Philip E ^a   Garcia Meijide, Mariane ^b   Holladay, E Blair ^c   Chuke, Ronald ^b   Payne, Jay ^b   Long, Amanda ^d   Siefers, Heather ^d   Demuth, Franklin ^e   Lorincz, Attila T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Digene Corporation   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d BBI Biotech Research Laboratories   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

HPV; Human papillomavirus; Hybrid Capture II; PreservCyt

Indexed keywords

VIRUS DNA;

ARTICLE; CONFIDENCE INTERVAL; FEMALE; FILTRATION BASED PROCESSING METHOD; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIQUID CYTOLOGY; MAJOR CLINICAL STUDY; PERFORMANCE; PRIORITY JOURNAL; STANDARD; TISSUE PREPARATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 13244249732     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/MEPB1TAMAD6Q13G3     Document Type: Article

References (17)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
2. Bosch FX, Manos MM, Munoz N, et al, for the International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
4. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348:489-490.
5. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
6. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
7. Ferreccio C, Bratti MC, Sherman ME, et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:815-823.
8. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
9. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
10. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
11. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
12. ACOG Committee on Practice Bulletins, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists, Number 45, August 2003: cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003;102:417-427.
13. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study: design, methods and characteristics of trial participants. Acta Cytol. 2000;44:726-742.
14. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
15. Sherman ME, Schiffman MH, Lorincz AT, et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer. 1997;81:89-97.
16. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000;92:397-402.
17. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003;188:1401-1405.